Trial Profile
Long-term Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus [EXTENSION OF 700245529]
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2019
Price :
$35
*
At a glance
- Drugs Neramexane (Primary)
- Indications Congenital nystagmus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merz Pharmaceuticals GmbH
- 11 Jun 2014 New trial record
- 30 Jun 2010
- 11 Dec 2009